Caricamento...
Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report
INTRODUCTION: Although there is a considerable amount of data in the literature on safe discontinuation of first-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia, little is known about discontinuation of second-generation tyrosine kinase inhibitor therapy. Most...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4160914/ https://ncbi.nlm.nih.gov/pubmed/25194418 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1752-1947-8-295 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|